Stone JH, Wallace Z, Perugino CA, et al. Final Results of an Open Label Phase 2 Study of a Reversible B Cell Inhibitor, Xmab®5871, in IgG4-Related Disease. ACR 2017, abstract 4L.
Fracturen en opioïden, SSRI’s en glucocorticoïden
jun 2019 | Osteoporose, RA